Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

Next Previous
Search
Trial Profile

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Calcineurin inhibitors; Corticosteroids
  • Indications Prurigo nodularis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY-PN PRIME2; PRIME2
  • Sponsors Sanofi; Sanofi-Aventis GmbH

    • Most Recent Events

    • 01 May 2023 Results of pooled analysis (from two studies NCT04183335 and NCT04202679) assessing the effect of Dupilumab in patients with prurigo nodularis published in the Nature Medicine
    • 21 Mar 2023 Results of pooled analysis from LIBERTY PN-PRIME and PRIME2, assessing proportion of patients achieving clinically meaningful improvement in these scores , presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of pooled analysis ((N=311 from two studies NCT04183335/NCT04202679) assessing the psychometric properties of Sleep-NRS in adult patients with prurigo nodularis presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top